Observational Study for Cancer Detection Using Blood Tests
This observational study is looking for people aged 21-80 who have been diagnosed with cancer or have a strong suspicion of cancer, and have not had cancer before or received treatment. The study aims to develop a new blood test that can detect cancer and identify where it started in the body. Researchers will collect blood samples to analyze changes in DNA and proteins that could signal the presence of cancer. The main goals are to see if the test can find cancer signals and pinpoint the cancer's origin at the time of the blood draw. This study is currently unclear on its recruitment status, but plans to enroll 20,000 participants.
- Study design
- This is an observational study that plans to enroll 20,000 participants. It uses a matched case-control design to build and test predictive models for cancer detection.
- What's involved
- If you join, you will have a blood draw. The study does not specify any other procedures or the duration of your participation.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types
At a glance
Conditions
NCT03869814
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
ClearNote Health, Inc.
San Diego, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Samuel Levy, Ph.D. · STUDY_DIRECTOR · ClearNote Health, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Detection of cancer signal in the cancer cohortBaseline
Evaluation of genomics, proteomic and epigenomics signals, such as 5-hydroxymethylcytosine (5hmC), contained in plasma, in comparison to these signals in plasma from non-cancer controls
- Detection of tissue of origin signal in the cancer cohortBaseline
Evaluation of genomics, proteomic and epigenomics signals, such as 5-hydroxymethylcytosine (5hmC), contained in plasma, in comparison to these signals from non-cancer controls